Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Deegan

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Blood Cells, Molecules & Diseases|November 15, 2016
Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome surveyHeather Lau, Nadia Belmatoug, Patrick Deegan, et al.
Plos One|February 3, 2018
Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United KingdomJulian F Guest, Andy Ingram, Nadia Ayoub, et al.
Bone|June 4, 2024
Deep learning-based quantification of osteonecrosis using magnetic resonance images in Gaucher diseaseBoliang Yu, Tristan Whitmarsh, Philipp Riede, et al.
Metabolites|November 26, 2024
Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing OsteonecrosisSimona D'Amore, Kenneth Eric Poole, Uma Ramaswami, et al.
BMJ Neurology Open|December 26, 2025
Diagnosis, management and monitoring of patients with Pompe disease in the UKJordi Díaz-Manera, Alexander Broomfield, James Davison, et al.
Journal of Inherited Metabolic Disease|February 19, 2026
Maternal and Fetal Outcomes in Imiglucerase-Treated Patients With Gaucher Disease: Real-World Evidence From the International Collaborative Gaucher Group (ICGG) Gaucher Registry Pregnancy Sub-RegistryShoshana Revel-Vilk, Patrick Deegan, Debra Day-Salvatore, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 25, 2019
Gaucher Disease in Bone: From Pathophysiology to PracticeDerralynn Hughes, Peter Mikosch, Nadia Belmatoug, et al.
Journal of Clinical Medicine|May 25, 2024
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) RegistryPatrick Deegan, Heather Lau, Deborah Elstein, et al.
Journal of Clinical Medicine|September 9, 2022
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
Journal of Clinical Medicine|June 28, 2023
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158"Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Blood Cells, Molecules & Diseases|November 15, 2016
Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome surveyHeather Lau, Nadia Belmatoug, Patrick Deegan, et al.
Plos One|February 3, 2018
Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United KingdomJulian F Guest, Andy Ingram, Nadia Ayoub, et al.
Bone|June 4, 2024
Deep learning-based quantification of osteonecrosis using magnetic resonance images in Gaucher diseaseBoliang Yu, Tristan Whitmarsh, Philipp Riede, et al.
Metabolites|November 26, 2024
Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing OsteonecrosisSimona D'Amore, Kenneth Eric Poole, Uma Ramaswami, et al.
BMJ Neurology Open|December 26, 2025
Diagnosis, management and monitoring of patients with Pompe disease in the UKJordi Díaz-Manera, Alexander Broomfield, James Davison, et al.
Journal of Inherited Metabolic Disease|February 19, 2026
Maternal and Fetal Outcomes in Imiglucerase-Treated Patients With Gaucher Disease: Real-World Evidence From the International Collaborative Gaucher Group (ICGG) Gaucher Registry Pregnancy Sub-RegistryShoshana Revel-Vilk, Patrick Deegan, Debra Day-Salvatore, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 25, 2019
Gaucher Disease in Bone: From Pathophysiology to PracticeDerralynn Hughes, Peter Mikosch, Nadia Belmatoug, et al.
Journal of Clinical Medicine|May 25, 2024
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) RegistryPatrick Deegan, Heather Lau, Deborah Elstein, et al.
Journal of Clinical Medicine|September 9, 2022
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
Journal of Clinical Medicine|June 28, 2023
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158"Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
Pageof 5